The future role of gut hormones in the treatment of obesity
The future role of gut hormones in the treatment of obesity
复制标题
DOI：
10.1177/2040622313506730
复制
发表时间：
2014-01
影响因子：
3.5
通讯作者：
R. Troke;T. Tan;S. Bloom
中科院分区：
文献类型：
--
作者：
R. Troke;T. Tan;S. Bloom
无论是在医疗保健方面还是在经济结果方面，肥胖症的流行都带来了巨大的负担，而目前的医疗疗法不足以应对这一挑战。减肥手术是目前治疗肥胖的唯一方法，可以长期持续地减轻体重。这种手术的有利效果被认为至少部分是通过肠道激素如GLP-1， PYY， PP和oxyntomodulin在手术后的变化来调节的。这些激素随后成为肥胖治疗发展的有吸引力的新靶点。在这里，我们回顾了这些肠道肽的发展，作为当前和新兴的治疗肥胖的疗法。
The obesity pandemic presents a significant burden, both in terms of healthcare and economic outcomes, and current medical therapies are inadequate to deal with this challenge. Bariatric surgery is currently the only therapy available for obesity which results in long-term, sustained weight loss. The favourable effects of this surgery are thought, at least in part, to be mediated via the changes of gut hormones such as GLP-1, PYY, PP and oxyntomodulin seen following the procedure. These hormones have subsequently become attractive novel targets for the development of obesity therapies. Here, we review the development of these gut peptides as current and emerging therapies in the treatment of obesity.